Taxol
Company: Bristol-Myers Squibb
Approval Status: Approved August 1997
Treatment for: Kaposi's Sarcoma
Areas: Immunology/Infectious Diseases; Oncology
General Information
Other Useful Resources
The U.S. Food and Drug Administration approved Bristol-Myers Squibb's cancer drug Taxol for the treatment of AIDS-related Kaposi's Sarcoma. Taxol therapy reduces the size of patients' tumors and diminishes their symptoms and pain. Taxol helped a majority of patients who had failed other therapies.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
